Tuesday, 22 April 2014

Competitor Analysis ErbB / Her Receptor Antagonists

Competitor Analysis ErbB / Her Receptor Antagonists is a new market research publication announced by Reportstack. The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody  therapy has spurred the discovery and development of efficacy enhanced versions as well as of ErbB dual or multi-target therapies.
The report includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/Her family. In addition the report lists company-specific R&D pipelines of ErbB/Her receptor targeting molecular entities. Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

To view the table of contents and know more details please visit Competitor Analysis ErbB / Her Receptor Antagonists report.

No comments:

Post a Comment